4.7 Article

Targeted Proteomic Analysis Revealed Kinome Reprogramming during Acquisition of Radioresistance in Breast Cancer Cells

期刊

JOURNAL OF PROTEOME RESEARCH
卷 20, 期 5, 页码 2830-2838

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acs.jproteome.1c00075

关键词

quantitative proteomics; parallel-reaction monitoring; SILAC; kinase; kinome; breast cancer; radioresistance; TAF9

资金

  1. National Institutes of Health [R01 CA210072]

向作者/读者索取更多资源

The study utilized SILAC and PRM methods to investigate the differential expression of kinases in breast cancer cells, revealing that the differentially expressed kinase TAF9 enhances radioresistance in breast cancer cells and plays a role in upregulating genes associated with radioresistance.
Radiotherapy constitutes a major therapeutic modality for early management of breast cancer. Despite the high efficacy in treating breast cancer (BC), radiation resistance and tumor recurrence are major hurdles in breast cancer radiotherapy. Herein, stable isotope labeling by amino acids in cell culture (SILAC) was employed, along with the parallel-reaction monitoring (PRM)-based targeted quantitative proteomic method, to examine the differences in kinase protein expression in MCF-7 and MDA-MB-231 breast cancer cells and their corresponding radioresistant C6 and C5 clones. We quantified the relative protein expression levels of 300 and 281 kinases in C5/MDA-MB-231 and C6/MCF-7 pairs of breast cancer cells, respectively. We also showed that TAF9, which was one of the differentially expressed kinases, enhances radiation resistance in breast cancer cells. Moreover, a correlation analysis of gene expression suggested TAF9's role in upregulating the expression of genes involved with radioresistance. Overall, our study uncovered a large number of differentially expressed kinases accompanied with the acquisition of radioresistance and revealed a role of TAF9 in promoting radioresistance in breast cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据